- In November 2024, the U.S. Food and Drug Administration (FDA) granted 510(k) marketing clearance to Acuitive Technologies Inc. for CITREPORE, a synthetic bioactive bone void filler incorporating the company’s patented CITREGEN biomaterial technology. Once placed in a bone void, CITREPORE undergoes a predictable resorption process, gradually being replaced by the patient's natural bone. In addition, it releases Citrate, which plays a key role in metabolically guiding the bone healing process
- In April 2023, ZimVie Inc. announced the launch of two new additions to its biomaterials portfolio: the RegenerOss CC Allograft Particulate, a natural blend of cortical and cancellous bone particles designed for filling bony voids in various dental applications, and the RegenerOss Bone Graft Plug, a user-friendly grafting solution for filling extraction sockets and periodontal defects. Both grafting solutions are now available across North America
- In April 2023, Abyrx, Inc. announced that it had received additional FDA clearances for its MONTAGE Settable, Resorbable Bone Putty, approved for use as both a bone void filler and cranial bone cement. MONTAGE is a hand-moldable, hardening putty designed for intraoperative use, achieving bone-like properties within minutes of mixing and application
- In July 2022, Bone Solutions Inc. announced that it had received FDA 510(k) clearance for expanded indications of its Mg OSTEOINJECT. As the first drillable, adhesive, and injectable bone void filler in the U.S. to incorporate magnesium, a vital element for bone health and development, the product's expanded indication allows its use as an adjunct to hardware fixation, providing support to bone fragments during surgical procedures
- In March 2022, Synergy Biomedical, LLC, a developer of advanced biomaterial products, announced the launch of BIOSPHERE FLEX SP EXTREMITIES, a synthetic bioactive bone graft. Leveraging Synergy’s proprietary BIOSPHERE Technology, this sheet putty consists of spherical bioactive glass granules integrated with a porous collagen/sodium hyaluronate carrier, offering enhanced bone regeneration properties
Frequently Asked Questions
Companies such as Carl ABYRX, Inc. (U.S.), Arthrex, Inc. (U.S.), Bone Solutions, Inc. (U.S.), Synergy Biomedical, LLC (U.S.) and ZimVie Inc. (U.S.), are the major companies in the bone void filler market.
In November 2024, the U.S. Food and Drug Administration (FDA) granted 510(k) marketing clearance to Acuitive Technologies Inc. for CITREPORE, a synthetic bioactive bone void filler incorporating the company’s patented CITREGEN biomaterial technology. In April 2023, ZimVie Inc. announced the launch of two new additions to its biomaterials portfolio: the RegenerOss CC Allograft Particulate, a natural blend of cortical and cancellous bone particles designed for filling bony voids in various dental applications, and the RegenerOss Bone Graft Plug, a user-friendly grafting solution for filling extraction sockets and periodontal defects.
The countries covered in the bone void filler market are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Austria, Poland, Norway, Ireland, Hungary, Lithuania, rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Philippines, Thailand, Malaysia, Vietnam, Indonesia, Singapore, rest of Asia-Pacific, Brazil, Argentina, Chili, Colombia, Peru, Venezuela, Ecuador, Uruguay, Paraguay ,Bolivia, Trinidad And Tobago, Curaçao, rest Of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, rest of Middle East and Africa, Guatemala, Costa Rica, Honduras, EL Salvador, Nicaragua, and rest of Central America.
